Phase 3 Pancreatic Cancer Trial, Recruiting NCT05884255 Sponsor: Jiangsu HengRui Medicine Co., Ltd. Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT05884255
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give written consent to participate
  • People aged 18 to 75 years old, of any gender
  • People whose general health and ability to carry out daily activities is rated at a good level (ECOG score of 0 or 1 — confirm with trial site if unsure what this means)
  • People who have been diagnosed through a tissue biopsy with slow- or moderate-growing neuroendocrine tumours of the digestive system (stomach, intestines, or pancreas) that cannot be removed by surgery and have either spread to nearby areas or to other parts of the body

Who may not be able to join:

  • People who are known to have cancer that has spread to the brain — though people who have already been treated for brain metastases (with radiotherapy or surgery), have no symptoms, and whose scans show the condition has been stable for at least 24 weeks before the trial starts may still be considered (confirm with trial site)
  • People with heart conditions or heart-related symptoms that are not well managed
  • People with diabetes where blood sugar levels remain too high even with the best available medical treatment
  • People with severe bladder or urinary problems, including serious difficulty urinating, a blocked kidney due to urine backup, severe loss of bladder control, or those who require a permanent urinary catheter for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
6 July 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free survival (PFS) assessed by BICR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov